Tissue ACE phenotyping in prostate cancer.

Tissue ACE phenotyping in prostate cancer. Oncotarget. 2019 Oct 29;10(59):6349-6361 Authors: Danilov SM, Kadrev AV, Kurilova OV, Tikhomirova VE, Kryukova OV, Mamedov VN, Kamalov DM, Danilova NV, Okhobotov DA, Gayfullin NM, Evdokimov VV, Alekseev BJ, Kost OA, Samokhodskaya LM, Kamalov AA Abstract Epithelial cells of prostate express significant level of ACE and, as a result, seminal fluid has 50-fold more ACE than plasma. The substitution of highly specialized prostate epithelial cells by tumor cells results in dramatic decrease in ACE production in prostate tissues. We performed detailed characterization of ACE status in prostate tissues from patients with benign prostate hyperplasia (BPH) and prostate cancer (PC) using new approach- ACE phenotyping, that includes evaluation of: 1) ACE activity with two substrates (HHL and ZPHL); 2) the ratio of the rates of their hydrolysis (ZPHL/HHL ratio); 3) the ratio of immunoreactive ACE protein to ACE activity; 4) the pattern of mAbs binding to different epitopes on ACE - ACE conformational fingerprint - to reveal conformational changes in prostate ACE due to prostate pathology. ACE activity dramatically decreased and the ratio of immunoreactive ACE protein to ACE activity increased in PC tissues. The catalytic parameter, ZPHL/HHL ratio, increased in prostate tissues from all patients with PC, but was did not change for most |BPH patients. Nevertheless, prostate tissues of several patients dia...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research